As to immunotherapy, a study has shown that Pyk2 regulates the ability of T-cells to react against foreign antigens and cancers, suggesting the potential of Pyk2 inhibitors to increase T-cell conjugation in anti-tumor immunotherapy [48]. This evidence concerns the gene PTK2B and neoplasm.